CN Patent

CN105753867B — 一种改进的阿维巴坦钠中间体化合物的制备方法

Assigned to QILU PHARMACEUTICAL (HAINAN) CO Ltd · Expires 2018-03-27 · 8y expired

What this patent protects

本发明属于医药化学技术领域，具体涉及一种β‑内酰胺酶抑制剂药物阿维巴坦钠及其中间体的制备方法。本发明采用三乙基硅烷实现苄基脱除，免了现有技术中的氢化催化操作，使得反应条件更加温和，降低了安全风险，大大提高了产品收率和纯度，更适合规模化生产。

USPTO Abstract

本发明属于医药化学技术领域，具体涉及一种β‑内酰胺酶抑制剂药物阿维巴坦钠及其中间体的制备方法。本发明采用三乙基硅烷实现苄基脱除，免了现有技术中的氢化催化操作，使得反应条件更加温和，降低了安全风险，大大提高了产品收率和纯度，更适合规模化生产。

Drugs covered by this patent

Patent Metadata

Patent number: CN105753867B
Jurisdiction: CN
Classification: —
Expires: 2018-03-27
Drug substance claim: No
Drug product claim: No
Assignee: QILU PHARMACEUTICAL (HAINAN) CO Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.